Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05133336 · ClinicalTrials.gov registry record · Phase 2
Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis
A Phase 2 study, sponsored by Zydus Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 196
- Enrollment target
NCT05133336 is a Phase 2 study that has completed, run by Zydus Therapeutics. The registered enrollment target is 196 participants.
The verdict
NCT05133336, a Phase 2 study, has completed, sponsored by Zydus Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 196 participants
- Enrollment target
Study Summary
Saroglitazar Magnesium 1 mg and 2 mg tablets for treatment of subjects with Primary Biliary Cholangitis (PBC)
Interventions
- DRUG Placebo
- DRUG Saroglitazar Magnesium 1 mg
- DRUG Saroglitazar Magnesium 2 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2025-05-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05133336
The ClinicalTrials.gov registry entry for NCT05133336 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zydus Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05133336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05133336 about?
NCT05133336 is a clinical study titled "Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis". Saroglitazar Magnesium 1 mg and 2 mg tablets for treatment of subjects with Primary Biliary Cholangitis (PBC)
What is the current status of trial NCT05133336?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 196 participants. The study started on 2022-04-01. Estimated completion is 2025-05-07.
What interventions are being tested in trial NCT05133336?
The interventions under investigation include: Placebo (DRUG), Saroglitazar Magnesium 1 mg (DRUG), Saroglitazar Magnesium 2 mg (DRUG).
Who is sponsoring clinical trial NCT05133336?
This trial is sponsored by Zydus Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.